CorMedix Reports Transformational 2025 with $163M Net Income, Driven by Melinta Acquisition and DefenCath Growth

summarizeSummary

CorMedix reported a significant financial turnaround in 2025 with $163.1 million net income and 617% revenue growth, driven by the Melinta acquisition and DefenCath sales, despite a disclosed material weakness in internal controls and anticipated near-term reimbursement headwinds.

check_boxKey Events

• Strong Financial Turnaround

  Reported a net income of $163.1 million for 2025, a significant improvement from a $17.9 million net loss in 2024. Total revenue surged by 617% to $311.7 million, primarily from product sales.

• Transformational Melinta Therapeutics Acquisition

  Completed the acquisition of Melinta Therapeutics on August 29, 2025, for a total consideration of $453.7 million, significantly expanding the company's commercial platform and product portfolio.

• DefenCath Commercial Success & Reimbursement Outlook

  DefenCath is the largest revenue contributor, with commercial supply agreements covering approximately 60% of outpatient dialysis centers. Anticipates a significant decline in net pricing for Q3/Q4 2026 due to reimbursement transitions, but expects higher sales prices in 2027.

• Material Weakness in Internal Controls Identified

  Management identified a material weakness in internal control over financial reporting as of December 31, 2025, related to the review of significant non-routine transactions, which led to an immaterial error in the Melinta acquisition accounting. Remediation efforts are underway.

auto_awesomeAnalysis

CorMedix Inc. delivered a strong financial turnaround in 2025, achieving a net income of $163.1 million compared to a $17.9 million loss in 2024, on the back of a 617% surge in total revenue to $311.7 million. This significant growth was primarily fueled by the successful commercialization of DefenCath and the transformational acquisition of Melinta Therapeutics in August 2025. The Melinta acquisition, valued at $453.7 million, substantially expanded CorMedix's commercial portfolio with six infectious disease products and one cardiovascular product, alongside a BARDA contract with potential funding up to $144.6 million. While the company disclosed a material weakness in internal controls related to non-routine transactions and anticipates a temporary decline in DefenCath net pricing in Q3/Q4 2026 due to reimbursement changes, the overall strategic expansion and return to profitability are highly positive. Investors should monitor the remediation of the material weakness and the actual impact of the DefenCath reimbursement changes, as well as the progress of REZZAYO's Phase III trial and ongoing litigations.